Pfizer (PFE)
(Delayed Data from NYSE)
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 6:50 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 6:50 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
AstraZeneca's (AZN) Triple Combo COPD Therapy Gets EU Nod
by Zacks Equity Research
AstraZeneca (AZN) gets European approval for triple combination therapy, Trixeo Aerosphere for COPD. CHMP recommends approval of trastuzumab deruxtecan for breast cancer.
Gaming ETF (BJK) Hits a New 52-Week High
by Sweta Killa
This gaming ETF hits a new 52-week high. Are more gains in store for this ETF?
CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.
5 Stocks to Win Big as Coronavirus Vaccine Rollout Begins
by Tirthankar Chakraborty
Emergency approval of COVID-19 vaccines is a boon for stocks such as Trane Technologies (TT), United Parcel Service (UPS), FedEx (FDX), Pfizer (PFE) and Moderna (MRNA). Here's why -
US Starts COVID-19 Vaccine Drive: 5 Consumer Discretionary Picks
by Ritujay Ghosh
The COVID-19 vaccine comes as a relief, indicating that the economy might bounce back in the coming days helping stocks like WilliamsSonoma (WSM), Reynolds Consumer Products (REYN) and Spectrum Brands Holdings (SPB).
Vaccines Get to America, but Congressional Relief Lacking
by Mark Vickery
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Viatris (VTRS) to Cut Jobs as Part of Restructuring Initiative
by Zacks Equity Research
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
Key Reasons Why UPS Stock Should Grace Your Portfolio Now
by Zacks Equity Research
The surge in e-commerce growth in the current scenario is a huge boon for UPS.
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
6 Consumer Discretionary ETFs Riding on Holiday Fervor
by Sweta Killa
U.S. consumers grew more confident in the economy in early December on the prospects of a vaccine, which has bolstered the holiday mood.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Occidental Petroleum, Devon Energy, Diamondback Energy, Baker Hughes and Marathon Oil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Occidental Petroleum, Devon Energy, Diamondback Energy, Baker Hughes and Marathon Oil
Stocks Decline modestly, but Vaccine Optimism Promises a New Rally
by David Borun
A massive rollout of vaccine distribution is the best hope yet for a "return to normal."
ETFs to Win & Lose From the Surge in Oil Price
by Sweta Killa
Oil price has been on a surge in recent months buoyed by solid development on the COVID-19 vaccine front.
Biotech ETF (SBIO) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Colon Cancer
by Zacks Equity Research
Merck's (MRK) regulatory application seeking label expansion of Keytruda as first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer gets positive CHMP opinion.
5 High Earnings Yield Bets Amid an Uncertain Santa Rally
by Rimmi Singhi
Check out these five high earnings yield stocks that can make you rich, irrespective of the Santa rally or a year-end pullback.
COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod
by Kinjel Shah
FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.
5 Energy ETFs Making the Most of the Oil Rally
by Sweta Killa
After registering the best month ever, the energy sector continued its bullish trend on vaccine optimism,
Producer Price Index in Line With Expectations
by Zacks Equity Research
Producer Price Index in Line With Expectations
Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.
Government Shutdown Looms, Vaccine Nears Passage
by Mark Vickery
If the government shuts down, talks cease on pandemic relief allotments, including Pandemic Unemployment Assistance (PUA), which is due to expire the day after Christmas.
Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine
Moderna (MRNA) Starts COVID-19 Vaccine Study in Adolescents
by Zacks Equity Research
Moderna (MRNA) initiates development of its coronavirus vaccine candidate, mRNA-1273, in adolescent patients in a phase II/III study.